Related references
Note: Only part of the references are listed.The cumulative incidence of cisplatin-induced hearing loss in young children is higher and develops at an early stage during therapy compared with older children based on 2052 audiological assessments
Annelot J. M. Meijer et al.
CANCER (2022)
Prevalence and risk factors for cisplatin-induced hearing loss in children, adolescents, and young adults: a multi-institutional North American cohort study
Diana J. Moke et al.
LANCET CHILD & ADOLESCENT HEALTH (2021)
Toll-like receptor 4 is activated by platinum and contributes to cisplatin-induced ototoxicity
Ghazal Babolmorad et al.
EMBO REPORTS (2021)
Usefulness of current candidate genetic markers to identify childhood cancer patients at risk for platinum-induced ototoxicity: Results of the European PanCareLIFE cohort study
Thorsten Langer et al.
EUROPEAN JOURNAL OF CANCER (2020)
Predictors of cisplatin-induced ototoxicity and survival in chemoradiation treated head and neck cancer patients
Wendy A. Teft et al.
ORAL ONCOLOGY (2019)
Pharmacogenomics of Cisplatin-Induced Ototoxicity: Successes, Shortcomings, and Future Avenues of Research
Britt I. Drogemoller et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2019)
Recommendations for ototoxicity surveillance for childhood, adolescent, and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCare Consortium
Eva Clemens et al.
LANCET ONCOLOGY (2019)
Sodium thiosulfate halves the risk of cisplatin-induced hearing loss
David Killock
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Sodium Thiosulfate for Protection from Cisplatin-Induced Hearing Loss
P. R. Brock et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Effects of sodium thiosulfate versus observation on development of cisplatin-induced hearing loss in children with cancer (ACCL0431): a multicentre, randomised, controlled, open-label, phase 3 trial
David R. Freyer et al.
LANCET ONCOLOGY (2017)
Pharmacogenetic variants in TPMT alter cellular responses to cisplatin in inner ear cell lines
Amit P. Bhavsar et al.
PLOS ONE (2017)
Cisplatin is retained in the cochlea indefinitely following chemotherapy
Andrew M. Breglio et al.
NATURE COMMUNICATIONS (2017)
Association Between SLC16A5 Genetic Variation and Cisplatin-Induced Ototoxic Effects in Adult Patients With Testicular Cancer
Britt I. Drogemoller et al.
JAMA ONCOLOGY (2017)
Determinants of ototoxicity in 451 platinum-treated Dutch survivors of childhood cancer: A DCOG late-effects study
Eva Clemens et al.
EUROPEAN JOURNAL OF CANCER (2016)
Hearing Loss in Patients Who Received Cranial Radiation Therapy for Childhood Cancer
Johnnie K. Bass et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Comprehensive Audiometric Analysis of Hearing Impairment and Tinnitus After Cisplatin-Based Chemotherapy in Survivors of Adult-Onset Cancer
Robert D. Frisina et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Cisplatin-Associated Ototoxicity: A Review for the Health Professional
Jessica Paken et al.
JOURNAL OF TOXICOLOGY (2016)
Ototoxicity in Children With High-Risk Neuroblastoma: Prevalence, Risk Factors, and Concordance of Grading Scales-A Report From the Children's Oncology Group
Wendy Landier et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Replication of TPMT and ABCC3 Genetic Variants Highly Associated With Cisplatin-Induced Hearing Loss in Children
K. Pussegoda et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2013)
Understanding platinum-induced ototoxicity
Thorsten Langer et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2013)
Platinum-Induced Ototoxicity in Children: A Consensus Review on Mechanisms, Predisposition, and Protection, Including a New International Society of Pediatric Oncology Boston Ototoxicity Scale
Penelope R. Brock et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Risk factors for cisplatin-associated ototoxicity in pediatric oncology patients
Allison Yancey et al.
PEDIATRIC BLOOD & CANCER (2012)
S-Adenosyl-L-Methionine Increases Serum BUN and Creatinine in Cisplatin-treated Mice
Bernardo Ochoa et al.
ARCHIVES OF MEDICAL RESEARCH (2009)
Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy
Colin J. D. Ross et al.
NATURE GENETICS (2009)
Hearing loss, quality of life, and academic problems in long-term neuroblastoma survivors: Report from the Children's Oncology Group
James G. Gurney et al.
PEDIATRICS (2007)
Ototoxicity in children receiving platinum chemotherapy: Underestimating a commonly occurring toxicity that may influence academic and social development
KRG Knight et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Hearing health and care: The need for improved hearing loss prevention and hearing conservation practices
SA Fausti et al.
JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT (2005)
Predicting cisplatin ototoxicity in children: the influence of age and the cumulative dose
Y Li et al.
EUROPEAN JOURNAL OF CANCER (2004)
Platinum compound-related ototoxicity in children - Long-term follow-up reveals continuous worsening of hearing loss
P Bertolini et al.
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY (2004)
Bilateral hearing loss during vincristine therapy: A case report
MT Kalcioglu et al.
JOURNAL OF CHEMOTHERAPY (2003)
Bilateral transient hearing loss associated with vincristine therapy: Case report
I Aydogdu et al.
JOURNAL OF CHEMOTHERAPY (2000)
Share Paper
